DrugPatentWatch Database Preview➤ Subscribe for complete access
« Back to Dashboard
Ruxolitinib phosphateis the generic ingredient in two branded drugs marketed by Incyte Corp and is included in two NDAs. There are thirteen patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.
Ruxolitinib phosphate has two hundred and eighty-six patent family members in forty-seven countries.
There are two drug master file entries for ruxolitinib phosphate. One supplier is listed for this compound.
Summary for RUXOLITINIB PHOSPHATE
|Drug Master File Entries:||2|
|Finished Product Suppliers / Packagers:||1|
|Raw Ingredient (Bulk) Api Vendors:||56|
|Formulation / Manufacturing:||see details|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for RUXOLITINIB PHOSPHATE|
|DailyMed Link:||RUXOLITINIB PHOSPHATE at DailyMed|
Recent Clinical Trials for RUXOLITINIB PHOSPHATE
Identify potential brand extensions & 505(b)(2) entrants
|Zhengzhou University||Phase 4|
|Philipps University Marburg Medical Center||Phase 2|
|Hackensack Meridian Health||Phase 2|
Pharmacology for RUXOLITINIB PHOSPHATE
|Drug Class||Kinase Inhibitor |
|Mechanism of Action||Protein Kinase Inhibitors |
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Incyte Corp||JAKAFI||ruxolitinib phosphate||TABLET;ORAL||202192-004||Nov 16, 2011||RX||Yes||No||⤷ Try it Free||⤷ Try it Free||⤷ Try it Free|
|Incyte Corp||JAKAFI||ruxolitinib phosphate||TABLET;ORAL||202192-003||Nov 16, 2011||RX||Yes||No||⤷ Try it Free||⤷ Try it Free||⤷ Try it Free|
|Incyte Corp||JAKAFI||ruxolitinib phosphate||TABLET;ORAL||202192-005||Nov 16, 2011||RX||Yes||Yes||⤷ Try it Free||⤷ Try it Free||⤷ Try it Free|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|
|Patent Number||Supplementary Protection Certificate||SPC Country||SPC Expiration||SPC Description|
|2455382||CR 2017 00018||Denmark||⤷ Try it Free||PRODUCT NAME: RUXOLITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER RUXOLITINIB FOSFAT; REG. NO/DATE: EU/1/12/773/001-016/C(2015)1740 20150313|
|1966202||8/2013||Austria||⤷ Try it Free||PRODUCT NAME: RUXOLITINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/12/773/001-003 20120823|
|1966202||13C0007||France||⤷ Try it Free||PRODUCT NAME: RUXOLITINIB OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/12/773/001-003 20120828|
|>Patent Number||>Supplementary Protection Certificate||>SPC Country||>SPC Expiration||>SPC Description|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.